Combination treatment including targeted therapy for advanced hepatocellular carcinoma

Jianzhen Lin; Liangcai Wu; Xue Bai; Yuan Xie; Anqiang Wang; Haohai Zhang; Xiaobo Yang; Xueshuai Wan; Xin Lu; Xinting Sang; Haitao Zhao

doi:10.18632/oncotarget.11954

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Combination treatment including targeted therapy for advanced hepatocellular carcinoma

Jianzhen Lin, Liangcai Wu, Xue Bai, Yuan Xie, Anqiang Wang, Haohai Zhang, Xiaobo Yang, Xueshuai Wan, Xin Lu, Xinting Sang and Haitao Zhao _

PDF | HTML | How to cite

Oncotarget. 2016; 7:71036-71051. https://doi.org/10.18632/oncotarget.11954

Metrics: PDF 3205 views | HTML 3870 views | ?

Abstract

Jianzhen Lin1,*, Liangcai Wu1,*, Xue Bai1,*, Yuan Xie1, Anqiang Wang1, Haohai Zhang1, Xiaobo Yang1, Xueshuai Wan1, Xin Lu1, Xinting Sang1 and Haitao Zhao1,2

1 Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing, China

2 Center of Translational Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

* These authors contributed equally to this work

Correspondence to:

Xin Lu, email:

Xinting Sang, email:

Haitao Zhao, email:

Keywords: targeted therapy, combination treatment, hepatocellular carcinoma, molecular targeted agents

Received: June 01, 2016 Accepted: September 05, 2016 Published: September 10, 2016

Abstract

Management of advanced hepatocellular carcinoma (HCC), one of the most lethal cancers worldwide, has presented a therapeutic challenge over past decades. Most patients with advanced HCC and a low possibility of surgical resection have limited treatment options and no alternative but to accept local or palliative treatment. In the new era of cancer therapy, increasing numbers of molecular targeted agents (MTAs) have been applied in the treatment of advanced HCC. However, mono-targeted therapy has shown disappointing outcomes in disease control, primarily because of tumor heterogeneity and complex cell signal transduction. Because incapacitation of a single target is insufficient for cancer suppression, combination treatment for targeted therapy has been proposed and experimentally tested in several clinical trials. In this article, we review research studies aimed to enhance the efficacy of targeted therapy for HCC through combination strategies. Combination treatments involving targeted therapy for advanced HCC are compared and discussed.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11954

Publication Alerts

Reviews:

Combination treatment including targeted therapy for advanced hepatocellular carcinoma

Abstract